These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]. Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317 [No Abstract] [Full Text] [Related]
7. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Rice G Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173 [No Abstract] [Full Text] [Related]
8. The role of interferons in the treatment of multiple sclerosis. Kelley CL J Neurosci Nurs; 1996 Apr; 28(2):114-20. PubMed ID: 8718760 [TBL] [Abstract][Full Text] [Related]
10. Current concepts in multiple sclerosis: Part II. Hanson LJ; Cafruny WA S D J Med; 2002 Nov; 55(11):477-81. PubMed ID: 12449589 [TBL] [Abstract][Full Text] [Related]
11. [Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis]. Losy J Neurol Neurochir Pol; 2000; 34(3 Suppl):63-9. PubMed ID: 10983302 [TBL] [Abstract][Full Text] [Related]
13. [Drug therapy of multiple sclerosis]. Kinnunen E Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889 [No Abstract] [Full Text] [Related]
14. Rebif offers another option for treating multiple sclerosis. Ryan M J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017 [No Abstract] [Full Text] [Related]
15. [A short history of beta-interferon therapy of multiple sclerosis]. Stock G; Horowski R Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113 [TBL] [Abstract][Full Text] [Related]
16. Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination. Pirko I; Kuntz NL; Patterson M; Keegan BM; Weinshenker BG; Rodriguez M Neurology; 2003 May; 60(10):1697-9. PubMed ID: 12771272 [TBL] [Abstract][Full Text] [Related]
17. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Achiron A; Barak Y; Gail M; Mandel M; Pee D; Ayyagari R; Rotstein Z Breast Cancer Res Treat; 2005 Feb; 89(3):265-70. PubMed ID: 15754125 [TBL] [Abstract][Full Text] [Related]
18. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
19. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials. Sørensen PS Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048 [TBL] [Abstract][Full Text] [Related]
20. Editorial: Licensing and Use of New Therapies in MS: Where Are We Going? Hurwitz B Int MS J; 2005 Aug; 12(2):39-41. PubMed ID: 16417813 [No Abstract] [Full Text] [Related] [Next] [New Search]